About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 213 record(s)
Req # A-2022-000037
Adverse Drug Reactions (ADRs) for RANITIDINE HYDROCHLORIDE, IRBESARTAN, CLOPIDOGREL BISULFATE. Report numbers: E2B_01687167, E2B_01270122, E2B_03570635, E2B_04694587, E2B_04651222.Organization: Health Canada
July 2022
Req # A-2022-000038
Adverse Drug Reactions (ADRs) for INSULIN GLARGINE, SARILUMAB, ZOPICLONE, DUPILUMAB. Report numbers: 000971525, 000967779, E2B_04683043, E2B_04709100, E2B_04694208.Organization: Health Canada
July 2022
Req # A-2022-000041
Adverse Drug Reactions (ADRs) for Zostavax II. Report numbers: E2B_01742359, E2B_01747192, E2B_02271205, E2B_02307576, E2B_02162521, E2B_00719137, E2B_00890322, E2B_02157290, E2B_02548174, E2B_02464454.Organization: Health Canada
July 2022
Req # A-2022-000044
Adverse Drug Reaction (ADR) for Zostavax II. Report number: E2B_02235603.Organization: Health Canada
July 2022
Req # A-2022-000045
Adverse Drug Reactions (ADRs) for ZOSTAVAX II. Report numbers: E2B_02321852, E2B_02456455, E2B_02559448, E2B_00399116. ADR for BRIDION. Report number: 000737460. ADRs for CANCIDAS. Report numbers: E2B_02786566, E2B_02790699, E2B_02233985.Organization: Health Canada
July 2022
Req # A-2022-000055
Adverse Drug Reactions (ADRs) for Dexilant. Report numbers: E2B_05049733, E2B_05027959, E2B_04997641. ADRs for ENTYVIO. Report numbers: E2B_04988450, E2B_05037027, E2B_05010527, 000979424. ADR for Vedolizumab. Report number: E2B_05079036. ADR for Ixazomib. Report number: E2B_05011569. ADR for Ondansetron. Report number: E2B_04998974.Organization: Health Canada
July 2022
Req # A-2022-000057
Adverse Drug Reaction (ADR). Report number: E2B_03931887.Organization: Health Canada
July 2022
Req # A-2022-000063
Adverse Drug Reactions (ADRs) for Mesalazine. Report numbers: 000978470, 000981367. ADR for Mesalamine. Report number: E2B_05076794. ADRs for C1 Esterase Inhibitor (Human). Report numbers: E2B_05005315, E2B_05050243, E2B_04959588. ADR for GAMMAGARD LIQUID. Report number: 979947. ADRs for Immunoglobulin (human). Report numbers: E2B_04999330, E2B_05080402, E2B_05008731.Organization: Health Canada
July 2022
Req # A-2022-000065
Adverse Drug Reactions (ADRs) for Immunoglobulin (human). Report numbers: E2B_05023522, E2B_05075235, E2B_05078453, E2B_05008371, E2B_05043180, 000981354. ADRs for Agalsidase alfa. Report numbers: E2B_05049007, E2B_04983028. ADR for Lanadelumab. Report number: E2B_04978267.Organization: Health Canada
July 2022
Req # A-2022-000076
Adverse Drug Reaction (ADR) for METFORMIN HYDROCHLORIDE. Report number: E2B_05082566.Organization: Health Canada
July 2022